Alkermes Plc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alkermes Plc. on August 15, 2025, with the earliest event reported on that date. The filing details two primary corporate actions: the entry into a material definitive agreement regarding an authorized generic product and the initiation of patent infringement litigation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. Financial implications are described qualitatively:
- Revenue Model: Under the new agreement, Alkermes will receive payment for supply at a premium to fully burdened manufacturing costs and will share in Net Profits from sales.
- Volume Cap: The supply of the authorized generic product is capped at approximately 15% of 2024 VIVITROL unit sales.
Material Changes and Agreements
Authorized Generic Agreement (Item 1.01)
On September 9, 2025, Alkermes Pharma Ireland Limited (APIL) entered into an agreement with Amneal Pharmaceuticals LLC to distribute an authorized generic version of VIVITROL (naltrexone for extended-release injectable suspension) in the United States.
- Term: One year beginning on the date of a Third Party ANDA Product Launch.
- Condition: If a Third Party ANDA Product Launch does not occur within 90 days after January 15, 2027, Amneal loses distribution rights.
- Profit Sharing: Parties will share Net Profits from sales of the Amneal AG Product.
Patent Litigation (Item 8.01)
Alkermes subsidiaries filed patent infringement lawsuits in the U.S. District Courts for New Jersey and Delaware against Teva, Apotex, and MSN.
- Subject: Generic versions of LYBALVI (olanzapine and samidorphan tablets).
- Trigger: Receipt of "paragraph IV certification" notices alleging invalidity or non-infringement of patents expiring between 2032 and 2041.
- Impact: Litigation triggered stays of FDA approval for the respective ANDAs for up to 30 months under the Hatch-Waxman Act.
Outlook, Risks, and Management Commentary
Management Stance: Alkermes intends to "vigorously defend" its intellectual property regarding LYBALVI.
Risks and Contingencies:
- Generic Competition: The VIVITROL agreement is contingent on a third-party generic launch; if this does not occur by the specified deadline, the agreement terminates.
- Legal Uncertainty: The outcome of the LYBALVI lawsuits is uncertain, though the filing of suits has temporarily blocked generic market entry for up to 30 months.
- Termination Rights: The VIVITROL agreement may be terminated if Amneal launches a non-authorized generic version of VIVITROL.
Key Facts for Investor Verification
- Verify the exact date of the "Third Party ANDA Product Launch" for VIVITROL to determine the start and potential expiration of the Amneal agreement.
- Monitor the status of the 30-month FDA approval stays for LYBALVI generic applications filed by Teva, Apotex, and MSN.
- Review the full text of the AG Agreement (to be filed as an exhibit to the Q3 2025 Form 10-Q) for specific profit-sharing percentages and termination clauses.
- Assess the impact of the 15% unit sales cap on VIVITROL revenue projections for the 2025-2026 period.